93
Participants
Start Date
July 31, 2023
Primary Completion Date
May 22, 2026
Study Completion Date
June 12, 2026
Efanesoctocog alfa
Recombinant coagulation factor VIII Fc-von Willebrand Factor-XTEN fusion protein (rFVIIIFc-VWF-XTEN)
Investigational Site, Vienna
Investigational Site, Zagreb
Investigational Site, Brno
Investigational Site, Prague
Investigational Site, Bordeaux
Investigational Site, Le Kremlin-Bicêtre
Investigational Site, Marseille
Investigational Site, Strasbourg
Investigational Site, Berlin
Investigational Site, Frankfurt
Investigational Site, Giessen
Investigational Site, Hamburg
Investigational Site, Athens
Investigational Site, Dublin
Investigational Site, Catanzaro
Investigational Site, Florence
Investigational Site, Naples
Investigational Site, Parma
Investigational Site, Rome
Investigational Site, Utrecht
Investigational Site, Oslo
Investigational Site, Ljubljana
Investigational Site, Barcelona
Investigational Site, Madrid
Investigational Site, Oviedo
Investigational Site, Lund
Investigational Site, Solna
Investigational Site, Canterbury
Investigational Site, Newcastle upon Tyne
Investigational Site, Oxford
Lead Sponsor
Collaborators (1)
Syneos Health
OTHER
Swedish Orphan Biovitrum
INDUSTRY